CVS Health sees 51,620 calls bought. CVS Health stock falls 4.27 percent

Published on 10/22/2026 at 11:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Call volume reached 51,620 contracts versus 17,056 typically on October 22, 2026. CVS Health stock costs EUR 82.67, 4.27 percent below Xetra close.

Dates frame the valuation

CVS Health saw 51,620 call options bought on October 22, 2026.
Third-quarter results are scheduled for November 4, 2026.
CVS Health stock trades at EUR 82.67 at 11:34 a.m. CEST at Lang & Schwarz on October 22, 2026, 4.27 percent below the Xetra close of October 21, 2026.

Moderner Apothekenverkaufsraum mit Apothekerin und Kundin vor Medikamentenregalen — CVS Health Corp. zeigt fotorealen Apothekenverkaufsraum mit Apothekerin und Kundin, ISIN US1266501006, Illustration mit AI erstellt.

CVS Health Corp. (ISIN US1266501006) was trading at EUR 82.67 at Lang & Schwarz on October 22, 2026, at 11:34 a.m. CEST, down 4.27 percent versus the Xetra close of October 21, 2026, at EUR 86.36. MarketBeat reported that traders bought 51,620 call options on October 22, compared with typical volume of 17,056 contracts.

Options activity meets earnings timing

The options figure gives the current market story a concrete measure, but it does not establish why traders acted. The next scheduled results provide the clearest near-term test for the healthcare group's outlook.

According to CVS Health, the company will discuss third-quarter 2026 financial results on November 4, 2026, during an 8:00 a.m. ET conference call. As of June 30, 2026, CVS Health had approximately 9,000 retail pharmacies, more than 1,000 walk-in and primary care clinics, and approximately 87 million pharmacy benefit plan members.

What changed before the next report?

The latest reported quarter showed revenue of USD 106.10 billion and adjusted earnings per share of USD 2.58, according to MarketBeat. Revenue was 7.30 percent higher than a year earlier, while earnings per share exceeded the USD 1.87 consensus estimate by USD 0.71 in the second quarter of 2026.

The same report cited fiscal 2026 earnings-per-share guidance of USD 7.90 to USD 8.10. It also reported that Sanford C. Bernstein reaffirmed an outperform rating and a USD 112.00 target on September 9, 2026, while Cantor Fitzgerald reiterated a neutral rating on October 9, 2026.

Three dates frame the setup

CVS Health's recent sequence runs from the August 5, 2026, quarterly report with USD 106.10 billion in revenue, through the September 9, 2026, Bernstein target of USD 112.00, to the October 22, 2026, options activity involving 51,620 calls. The chronology puts the November report at the center of the near-term discussion.

The next substantiated dates are November 2, 2026, for payment of the USD 0.665 quarterly dividend, and November 4, 2026, for the third-quarter results call. Both dates are reported by MarketBeat and CVS Health, respectively.

Stock reflects a sharper test

The share price is 4.27 percent below the October 21 Xetra close, giving the November 4 report greater importance for investors weighing the gap between the latest earnings figures and the next update. The primary listing is on the NYSE, where MarketBeat cited a USD 69.51 to USD 110.68 52-week range and USD 119.74 billion market capitalization on October 22, 2026.

CVS Health was trading at EUR 82.67 at Lang & Schwarz on October 22, 2026, at 11:34 a.m. CEST, 4.27 percent below the Xetra close of October 21, 2026, at EUR 86.36. The further course of trading is shown by the continuously updated real-time quote of CVS Health stock.